Immune Design (IMDZ) Tops Q1 EPS by 8c

Immune Design (NASDAQ: IMDZ) reported Q1 EPS of ($0.56), $0.08 better than the analyst estimate of ($0.64). Revenue for the quarter came in at $1.9 million versus the consensus estimate of $1.3 million.

For earnings history and earnings-related data on Immune Design (IMDZ) click here.

You May Also Be Interested In

• Worthington Steel, Inc. (WS) Misses Q4 EPS by 3c
• Jefferies Financial Group (JEF) Misses Q2 EPS by 22c
• JPMorgan Starts Accton Technology Corp. (2345:TT) at Overweight